Biosynth Carbosynth (Compton, UK) has entered into agreement with Cancer Research Technology Ltd (CRT) to supply novel chemical probes and compounds for cancer research. The agreement aims to increase the impact and commercial availability of chemical probes developed by CRT to the global research community.
CRT focuses on developing high quality, chemical probes to investigate the biology and therapeutic potential of a wide variety of cancer targets. The first molecule to emerge from this agreement is the inhibitor of checkpoint kinase 2, CCT 241533, which was developed at the Institute of Cancer Research, Sutton, UK.
We will be introducing more novel chemical probes through this agreement and made them available to the global research community. Novel chemical probes for different cancer targets have been accelerating scientific research with the goal of driving the development of novel therapeutic molecules.
"We are excited to be working with CRT to offer these compounds to researchers worldwide" said Dr Duncan Crawford, Marketing Director at Biosynth Carbosynth. "The partnership between Biosynth Carbosynth and CRT will provide our customers with a guaranteed supply of CRT probe molecules from a trusted commercial source."
About Cancer Research Technology
Cancer Research UK’s Commercial Partnerships team, a component of the Research and Innovation division, develops promising ideas into successful cancer therapeutics, vaccines, diagnostics and enabling technologies. They are dedicated to advancing discoveries to beat cancer by developing and commercialising exciting new discoveries in cancer research. Our deep understanding of both academia and industry enables us to translate promising research into commercial propositions to deliver patient benefit and commercial value that will support further cancer research.
About Biosynth Carbosynth
Biosynth Carbosynth is the new global brand created from the merger of two key players in the fine chemicals market and is a leading supplier of life science reagents to the global research community. We have a long tradition of working alongside pharmaceutical companies and universities to bring new discoveries out of the laboratory and into the commercial arena. Since 1982, Biosynth Carbosynth has been committed to making new discoveries possible by providing the highest performing and most innovative range of research reagents available and a trusted and valued resource for life scientists worldwide.